Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Godavari Biorefineries receives patent from CNIPA
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Subscribe To Our Newsletter & Stay Updated